Biliary Tract Cancer Fail Is Another Blow for Merck KGaA/GSK's Bintrafusp
Objective Response Rate Too Low For Filing
Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.
